CJ gains access to RaQualia's acid pump antagonists
This article was originally published in Scrip
Executive Summary
RaQualia Pharma, a Japanese venture spun out from Pfizer research, has reached a licensing deal for two of its pipeline projects with a leading South Korean pharma firm.